2-[(2-Amino-3-phenylpropanoyl)amino]ethanesulfonic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(2-Amino-3-phenylpropanoyl)amino]ethanesulfonic acid
• 化学式: C₁₁H₁₆N₂O₄S
• 分子量: 272.32
• InChiKey: FRJZFTWFVMNHCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
  申请人：Neurochem (International) Limited

  公开号：EP1609467A1

  公开（公告）日：2005-12-28

  Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described.

  本文描述了用于抑制受试者体内糖胺聚糖（GAG）相关分子相互作用的治疗化合物和方法，无论其临床环境如何。
• Method for treating amyloidosis
  申请人：QUEEN'S UNIVERSITY AT KINGSTON

  公开号：EP1614432A2

  公开（公告）日：2006-01-11

  Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

  本文描述了抑制受试者体内淀粉样蛋白沉积的治疗化合物和方法，无论其临床环境如何。通过向受试者施用有效量的治疗化合物来抑制淀粉样蛋白沉积，该化合物包含阴离子基团和载体分子或其药学上可接受的盐，从而抑制淀粉样蛋白生成蛋白和基底膜成分之间的相互作用。首选的阴离子基团是磺酸盐和硫酸盐。优选的载体分子包括碳水化合物、聚合物、肽、肽衍生物、脂肪族基团、脂环族基团、杂环族基团、芳香族基团及其组合。
• Methods for modulating neuronal cell death
  申请人：——

  公开号：US20020022657A1

  公开（公告）日：2002-02-21

  The invention provides methods of inhibiting A&bgr;-induced neuronal cell death. The invention further provides methods of providing neuroprotection to a subject and methods of treating a disease state characterized by A&bgr;-induced neuronal cell death in a subject. Methods of inhibiting p75 receptor mediated neuronal cell death, as well as methods of treating a disease state in a subject characterized by p75 receptor mediated neuronal cell death are provided.

  本发明提供了抑制A&bgr;诱导的神经细胞死亡的方法。本发明进一步提供了为受试者提供神经保护的方法，以及治疗受试者以A&bgr;诱导的神经元细胞死亡为特征的疾病状态的方法。本发明提供了抑制p75受体介导的神经元细胞死亡的方法，以及治疗以p75受体介导的神经元细胞死亡为特征的受试者疾病状态的方法。
• Methods and compositions to treat glycosaminoglycan-associated molecular interactions
  申请人：Queen's University

  公开号：US20020193395A1

  公开（公告）日：2002-12-19

  Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described.

  本文描述了用于抑制受试者体内糖胺聚糖（GAG）相关分子相互作用的治疗化合物和方法，无论其临床环境如何。
• Compounds and methods for modulating cerebral amyloid angiopathy
  申请人：——

  公开号：US20030003141A1

  公开（公告）日：2003-01-02

  The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject.

  本发明提供了抑制脑淀粉样蛋白血管病变的方法。本发明进一步提供了治疗以脑部淀粉样蛋白血管病变为特征的疾病状态的方法。